| 2.07 0.05 (2.48%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.89 | 1-year : | 3.38 |
| Resists | First : | 2.48 | Second : | 2.89 |
| Pivot price | 1.91 |
|||
| Supports | First : | 1.88 | Second : | 1.51 |
| MAs | MA(5) : | 2.02 |
MA(20) : | 1.95  |
| MA(100) : | 3.07 |
MA(250) : | 2.88 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 79.9 |
D(3) : | 76.6 |
| RSI | RSI(14): 48.2 |
|||
| 52-week | High : | 8.81 | Low : | 1.16 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ACXP ] has closed below upper band by 22.8%. Bollinger Bands are 42.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.08 - 2.09 | 2.09 - 2.11 |
| Low: | 1.95 - 1.97 | 1.97 - 1.98 |
| Close: | 2.05 - 2.07 | 2.07 - 2.09 |
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Mon, 15 Apr 2024
Acurx Pharmaceuticals, Inc. Rings the Closing Bell - Nasdaq
Mon, 18 Mar 2024
Earnings call: Acurx Pharmaceuticals Reports Positive Phase IIb Results - Investing.com
Fri, 26 Jan 2024
New to The Street Announces Episode 551, Five Corporate Interviews, Airing on the FOX Business Network, Monday ... - GlobeNewswire
Mon, 22 Jan 2024
Acurx Stock: Sell-off Presents Opportunity Before Upcoming Data Release - Seeking Alpha
Wed, 17 Jan 2024
Acurx stock plunges 26% amid Phase 2 data release for C. diff drug (NASDAQ:ACXP) - Seeking Alpha
Wed, 17 Jan 2024
Acurx's ibezapolstat posts positive phase II data but stock slips - BioWorld Online
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 16 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 15.2 (%) |
| Held by Institutions | 11.6 (%) |
| Shares Short | 337 (K) |
| Shares Short P.Month | 292 (K) |
| EPS | -1.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.31 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -106.7 % |
| Return on Equity (ttm) | -243.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -1.8 |
| PEG Ratio | 0 |
| Price to Book value | 6.46 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.33 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|